Vaccine

Iovance Biotherapeutics Completes Biologics License Application (BLA) Submission for Lifileucel in Advanced Melanoma

First TIL Therapy BLA Submission to U.S. Food and Drug AdministrationSAN CARLOS, Calif., March 24, 2023 (GLOBE NEWSWIRE) -- Iovance…

1 year ago

Renowned Public Health Advisor Jim O’Neill Joins Board of Directors of ADvantage Therapeutics

Appointment announced today at inaugural Entrepreneurship, Longevity and Biotech Conference Held in Boca RatonBOCA RATON, Fla. and VIENNA, Austria, March…

1 year ago

Vaccitech Reports Full-Year 2022 Financial Results and an Update on Corporate Developments

OXFORD, United Kingdom, March 24, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) (the Company, we or us), a clinical-stage…

1 year ago

CancerVax CEO Ryan Davies Speaks with University of Utah Chemistry Professor about the Future of Therapeutic Research

Dr. Ryan Looper, a chemistry Professor at the University of Utah, sat down with CancerVAX CEO Ryan Davies to discuss…

1 year ago

Ultimovacs ASA: Annual Report 2022

Oslo, 24 March 2023: Ultimovacs ASA (“Ultimovacs”, ticker ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, announces that…

1 year ago

AstriVax, an innovative vaccine platform company, establishes scientific advisory board with world renowned leaders in vaccine development

Emmanuel Hanon, PhD, will chair the company’s scientific advisory board. Professor Peter Piot (MD, PhD) and Professor Patrick Soentjens (MD,…

1 year ago

Tonix Pharmaceuticals Presents Non-Clinical Data on TNX-2900 for the Potential Treatment of Hyperphagia in Adolescents and Young Adults with Prader-Willi Syndrome at the Rare Disease Innovation and Partnership Summit

CHATHAM, N.J., March 23, 2023 (GLOBE NEWSWIRE) --  Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced…

1 year ago

IMUNON to Hold Fourth Quarter 2022 Financial Results and Business Update Conference Call on Thursday, March 30, 2023

LAWRENCEVILLE, N.J., March 23, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated…

1 year ago

Vaccinex, Inc. to Present at the 2023 AAIC Advancements: Immunity Conference

March 24th presentation to highlight learnings related to pepinemab’s mechanism of action in both Huntington’s Disease and Alzheimer’s DiseaseROCHESTER, N.Y.,…

1 year ago

Evaxion presents a new source of AI-derived immunotherapeutic targets strongly associated with the overall survival of cancer patients

Evaxion’s AI technology has led to the identification of new viral targets for cancer immunotherapyThis potentially enables treatment for patients…

1 year ago